Mendelspod Podcast

31:47

State of Sequencing 2018 with Keith Robison, Omics!...

Mendelspod Podcast ·

2018/02/20

Sequencing geeks are fresh off the trail from AGBT, and it’s time for our annual look at the sequencing tools space. This year we sit down with the longtime Omics! Omics! blogger, Keith Robison, who not only can answer all your questions about the topic, he even knows which sequencer you’re using right now, and in which department.Keith jauntily runs through the Big 3--Illumina, Pac-Bio, and Oxford Nanopore--and has a few odds and ends to say about the "niche developers." This is a public episode

en

24:47

Direct RNA-Seq Project Shows Nanopore Sequencing Can...

Mendelspod Podcast ·

2018/02/06

Nanopore sequencing has arrived. Passing test after test this past year--including one we discuss today--this technology which was being hyped decades ago is delivering on its promise.Winston Timp joins us today. He's an assistant professor at Johns Hopkins and one of the leaders on a recent large scale project to directly sequence RNA on an array of nanopores. Winston's is the first in a series of shows we've lined up with users of Oxford Nanopore's technology.Why RNA-seq? Hasn’t this been done

en

24:34

January 2018 Review Show with Nathan and Laura:...

Mendelspod Podcast ·

2018/02/01

Some stocks are up on news of big biotech mergers, but others are down on hearing of the latest difficulties of gene therapy. One thing’s for sure—blood diseases are where it’s at.Speaking of the latest difficulties, we start our January review by going back to that paper out of Stanford about a new obstacle to using CRISPR as a new drug platform. It’s called the human immune system. Major roadblock or small warning light? This is a public episode. If you'd like to discuss this with other

en

19:09

Going Beyond the Liver with RNAi: Chris Anzalone of...

Mendelspod Podcast ·

2018/01/23

Fifteen years ago, folks in the industry were buzzing about RNAi the way they talk about CRISPR today. Then things went quiet for the technology, at least in the news. Until last year.In September of 2017, Alnylam Pharmaceuticals, the leader in the RNAi space, announced such positive phase III study results that most experts in the business expect an FDA approval soon. It will be the first for an RNAi drug. This is a public episode. If you'd like to discuss this with other subscribers or get

en

26:05

Vice Chancellor Keith Yamamoto on UCSF’s Role in...

Mendelspod Podcast ·

2018/01/15

A major chapter in the history of medicine has been written by UC San Francisco. They are writing the next for precision medicine. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

37:57

The Global Business of Reproductive Genetic Testing...

Mendelspod Podcast ·

2018/01/11

Reproductive testing is one of the hottest fields in which genetics is going mainstream, a field hurdling us rapidly into the future. It’s an area we’ll be following closely in 2018.Gary Harton serves as the Chief Operating Officer in the US for Igenomix, a company in the reproductive testing space with a vast global presence. The company has labs in the US, Japan, India, Turkey, Rome, Brazil, Mexico, Canada, and are headquartered in Valencia, Spain. This is a public episode. If you'd like to

en

36:41

The State of Genomics 2018 with Nathan, Laura, and Misha

Mendelspod Podcast ·

2018/01/08

Our first show of the year is an outlook on genomics for 2018. To do this we’re joined by our regular commentators, Nathan Pearson and Laura Hercher, and also by a special guest to mix things up a bit, Misha Angrist, Associate Professor at Duke University and Editor in Chief of Genome Magazine. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

31:25

Sharon Begley of STAT News

Mendelspod Podcast ·

2017/12/19

Sharon Begley joins us for our last show of the year to look back over some of the year’s top stories. She’s the senior science writer at STAT News where she covers genetics, cancer, neuroscience and other fields of biomedical research. Prior to joining STAT, Sharon was the senior health and science correspondent at Reuters, the science columnist at the Wall Street Journal, and the science editor at Newsweek. This is a public episode. If you'd like to discuss this with other subscribers or get

en

27:04

A New “Middle Way” for Genomics, with Physical...

Mendelspod Podcast ·

2017/12/13

“I love low tech,” says today’s guest.It’s not your typical catch phrase for 2017. But then today’s guest is not your typical genome scientist.A professor in the Department of Chemical Physics at Tel Aviv University in Israel where he runs the NanoBioPhotonix Lab, Yuval Ebenstein came to the genome from an unusual direction. As a physical chemist he started working with DNA as “just a material.” This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus

en

26:40

Sara Demy on Biotech CEOs

Mendelspod Podcast ·

2017/12/04

Our topic today: biotech leadership. What makes a good biotech CEO? Are there unique issues to biotech and diagnostics that shape and demand a different kind of leadership? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

21:35

November 2017 with Nathan and Laura: The Stem Cell...

Mendelspod Podcast ·

2017/12/01

It didn’t take long to come up with our lead story for November’s month in review show. Looking at the pictures of the boy in Germany playing soccer after successful treatment of his rare skin disease is just the kind of images we had in mind when we first heard of stem cell therapies. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

23:54

Seattle Startup Takes Precision Oncology to the Next...

Mendelspod Podcast ·

2017/11/16

Carla Grandori was for thirty years a cancer researcher most recently at the Fred Hutch in Seattle. She had her personal reasons for working on cancer, she tells us in today’s show. Now, she’s the CEO and founder of SEngine, a startup offering something completely new for oncologists around the country.Carla says she was motivated to step out of the research lab when two patients came to her personally and asked her, “can you study my cancer?” This is a public episode. If you'd like to discuss

en

28:05

Immuno Oncology 2017: Looking Back, Looking Forward...

Mendelspod Podcast ·

2017/11/14

Immuno oncology is now the dominant topic at Mendelspod. From shows with CEOs presenting new panels of predictive biomarker tests, to the firsts at the FDA with the CAR-T approvals as well as the first approval of a drug (Merck’s Keytruda) based on a common biomarker (MSI) rather than on a tumor type, to scientists discussing rare cells of the immune system, we had more podcasts on this topic than any other in 2017. This is a public episode. If you'd like to discuss this with other subscribers or

en

26:15

Huh? 30 Million Americans Have a Rare Disease? Howard...

Mendelspod Podcast ·

2017/11/09

Here’s a title for you. Chief Genomics Officer. Today’s guest is also the VP of Genomic Medicine and a faculty investigator at the HudsonAlpha Institute for Biotechnology. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

26:58

With their Own Manufacturing Facility, Seattle...

Mendelspod Podcast ·

2017/11/07

The past few months have seen the first approvals at the FDA for CAR-T cancer therapies. But trials have been going on for years. And not just by big pharma.Today’s guest, Dr. Michael Jensen, is a researcher at Seattle Children’s Hospital and started his first CAR-T cell trial back in 2002.“It’s been a long road to get to the point where we understand enough about the science and physiology of this technology to make it work int he clinic," he tells us in today's interview. This is a public

en

24:53

With Immuno Oncology Comes a New Focus on Rare Cells

Mendelspod Podcast ·

2017/11/01

Modena, Italy is the town where one of the world's rarest cars were first developed and built: the Ferrari sports car. It’s also home to one of the world’s oldest universities where today’s guest spends his time studying rare human cells. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

22:17

We've Become Too Single Variant Centric, Says Deanna...

Mendelspod Podcast ·

2017/10/12

From 1999 to 2013, Deanna Church was a staff scientist at the NCBI where, for a time, she headed the Genome Reference Consortium. This was the effort to continually update, improve and maintain the reference genome. Then Deanna went into private industry, first to Personalis--a genome interpretation company, and now she’s Director of Applications at 10X Genomics--the tools company offering linked read sequencing technology. This is a public episode. If you'd like to discuss this with other

en

25:27

Clinicians Show High Demand for Single Cell...

Mendelspod Podcast ·

2017/10/05

If today's guest were a super hero, he'd be High Resolution Sequencing Man.Bobby Sebra is the Director of Technology Development at the Icahn Institute of Genomics and Multiscale Biology at Mt Sinai in New York. He has the complete arsenal of DNA sequencers in his lab. He specializes in long read applications, and today he goes into several of those spaces, including infectious disease and oncology.How has sequencing changed since we last had Bobby on a couple years ago, and how does he see it

en

25:41

September 2017 with Nathan and Laura: Venter Blunder,...

Mendelspod Podcast ·

2017/10/02

To honor Laura's pentametric thirst,We write the summary today in verse. Was it a quake that had no epicenter,That silly paper out by J. Craig Venter? And after years of silencing the marketHas RNAi at last knocked out its target? Then Nathan gives to yuppies devil's choice.Which one libs: gluten dough or GMOs? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

24:29

Charting the Dark Matter of Cancer Genomes with Jim...

Mendelspod Podcast ·

2017/09/26

We’ve heard a lot this year about the search for new structural variants and the hope that scientists will find new causal linkages for diseases such as cancer. But will the genome still yield dramatic genetic signatures such as KRAS, BRAF and EGFR that have been so helpful in cancer treatment?Today’s guest says, yes, and he’s on the trail. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

All Episodes

Similar Podcasts

Mendelspod Podcast

Theral Timpson

DMCN Journal

John Wiley & Sons Ltd

汪诘：科学有故事（主打）

科学有故事

天方烨谈

基因频道

Homesteading and Permaculture by Paul Wheaton

paul wheaton